Sermorelin · Research brief

What’s the Half-Life of Sermorelin? (Dosing Explained)

Real Peptides Research TeamEditorial

Updated June 12, 20268 min read

54 WORDS

Short answer

(Dosing Explained) Sermorelin's plasma half-life is approximately 10–20 minutes. One of the shortest elimination windows in peptide therapy. That's faster than most injected medications clear from circulation. What makes this counterintuitive is that sermorelin dosing protocols typically call for once-daily administration, often at bedtime, despite the compound vanishing from bloodstream within half an hour.

Key takeaways

Sermorelin's plasma half-life is 10–20 minutes, with complete clearance from circulation within 30–40 minutes post-injection.
Growth hormone release triggered by sermorelin peaks 30–60 minutes after administration and remains elevated for 2–4 hours, far outlasting the peptide's plasma presence.
Dosing frequency is determined by physiological GH pulse timing (every 3–5 hours, largest pulse at sleep onset) rather than sermorelin's circulation time.
Rapid enzymatic degradation by DPP-IV and neprilysin prevents tonic receptor activation, preserving GHRH receptor sensitivity over chronic use.
Sermorelin works by amplifying endogenous GH pulses. It cannot create GH release in individuals with depleted pituitary reserves or severe GH deficiency.
Protocols using 5-day-per-week dosing often outperform daily administration by allowing receptor resensitization during rest days.

What's the Half-Life of Sermorelin? (Dosing Explained)

Sermorelin's plasma half-life is approximately 10–20 minutes. One of the shortest elimination windows in peptide therapy. That's faster than most injected medications clear from circulation. What makes this counterintuitive is that sermorelin dosing protocols typically call for once-daily administration, often at bedtime, despite the compound vanishing from bloodstream within half an hour. The reason lies in the mechanism: sermorelin doesn't need to stay in circulation to work. It triggers a cascade. A pulse of endogenous growth hormone (GH) release from the anterior pituitary. That continues long after the peptide itself has degraded.

We've worked with researchers studying GH secretagogue kinetics across hundreds of protocols. The gap between sermorelin's circulation time and its functional window is the single most misunderstood element in peptide dosing design.

What's the half-life of sermorelin, and why does it matter for dosing?

Sermorelin has a plasma half-life of 10–20 minutes, meaning the peptide is enzymatically degraded and cleared from circulation within 30 minutes of subcutaneous injection. Despite this rapid clearance, sermorelin induces a pulsatile growth hormone release that peaks 30–120 minutes post-injection and can influence GH levels for several hours. Dosing frequency is determined by the GH pulse duration and physiological rhythm. Not by the peptide's circulation time.

Most peptide guides treat half-life as a dosing determinant across all compound classes. That framework breaks down with GH secretagogues like sermorelin. The peptide binds to growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary, triggering degranulation and GH secretion. Once that cascade initiates, the presence of sermorelin in plasma becomes irrelevant. The pituitary response follows its own kinetics. This article covers sermorelin's pharmacokinetic profile, why plasma half-life differs from functional half-life, how dosing protocols align with circadian GH rhythms, and what preparation or timing mistakes negate the intended pulsatile effect.

Sermorelin's Pharmacokinetic Profile

Sermorelin (GRF 1-29) is a synthetic analogue of the first 29 amino acids of naturally occurring growth hormone-releasing hormone. After subcutaneous injection, sermorelin enters systemic circulation within 5–10 minutes, reaching peak plasma concentration at approximately 15–20 minutes. The compound is degraded primarily by dipeptidyl peptidase-IV (DPP-IV) and neprilysin. Proteolytic enzymes that cleave peptide bonds at specific residues. This enzymatic degradation proceeds rapidly: plasma concentration drops to half its peak within 10–20 minutes, and to undetectable levels within 30–40 minutes.

What persists beyond sermorelin's clearance is the downstream effect. GH secretion triggered by sermorelin peaks 30–60 minutes post-injection and remains elevated for 2–4 hours depending on individual pituitary responsiveness and baseline GH reserve. This temporal disconnect is why dosing sermorelin every 10 minutes would produce no added benefit. The pituitary pulse is already underway. Functional efficacy is tied to the GH release window, not to maintaining plasma sermorelin levels.

Our team has reviewed kinetic data across peptide formulations in research settings. The pattern is consistent: sermorelin's brief circulation time does not limit its utility because the mechanism operates through receptor activation and signal transduction, not through sustained receptor occupancy. Compare this to long-acting GH secretagogues like CJC-1295 with DAC (Drug Affinity Complex), which extends half-life to 6–8 days through albumin binding. Those compounds work by maintaining continuous low-level receptor stimulation rather than mimicking physiological GH pulses.

Why Dosing Frequency Doesn't Match Half-Life

Physiological GH secretion follows a pulsatile pattern governed by the interplay between GHRH (stimulatory) and somatostatin (inhibitory). In healthy adults, GH pulses occur roughly every 3–5 hours, with the largest amplitude pulse occurring 60–90 minutes after sleep onset. Sermorelin dosing protocols mimic this rhythm by delivering a single nightly dose timed to coincide with natural nocturnal GH surge. Administering sermorelin at bedtime amplifies the endogenous pulse that would occur anyway. The peptide doesn't create a pulse from nothing, it enhances one already programmed by circadian biology.

This is mechanistically different from replacement therapy. Exogenous recombinant human growth hormone (rhGH) provides a constant elevation in serum GH regardless of physiological rhythm. Sermorelin, by contrast, works within the body's existing regulatory framework. It can only trigger GH release if the pituitary has adequate somatotroph density and stored GH reserves. That's why sermorelin effectiveness declines with age: pituitary GH stores diminish, and receptor sensitivity decreases. A 25-year-old with robust pituitary function may see a 300–500% increase in GH following sermorelin administration; a 65-year-old with depleted GH reserves may see only a 50–100% increase from the same dose.

The short half-life actually supports the therapeutic goal. Rapid clearance prevents tonic receptor activation, which would downregulate GHRH receptors and blunt subsequent responses. Pulsatile dosing preserves receptor sensitivity over time. This is why protocols using sermorelin five nights per week often outperform daily dosing in long-term studies. The two rest days allow receptor resensitization.

Half-Life of Sermorelin: Comparison with Other GH Secretagogues

Compound	Plasma Half-Life	Mechanism	Dosing Frequency	Professional Assessment
Sermorelin (GRF 1-29)	10–20 minutes	GHRH receptor agonist; triggers pulsatile GH release from pituitary	Once daily (bedtime preferred)	Shortest half-life but effective for mimicking natural GH pulses. Best for preserving physiological rhythm and receptor sensitivity.
CJC-1295 (no DAC)	~30 minutes	GHRH receptor agonist; similar to sermorelin but slightly more stable	1–3 times per week	Marginally longer half-life than sermorelin. Allows less frequent dosing while maintaining pulsatile pattern.
CJC-1295 with DAC	6–8 days	GHRH receptor agonist with albumin binding via Drug Affinity Complex	Once per week	Extended half-life produces continuous low-level GH elevation rather than pulses. May cause receptor desensitization over time.
Ipamorelin	~2 hours	Ghrelin receptor agonist (growth hormone secretagogue receptor, GHSR)	1–2 times daily	Longer functional window than sermorelin. Often stacked with GHRH analogues for synergistic effect.
GHRP-2	~30 minutes (plasma)	Ghrelin receptor agonist; stimulates appetite and GH release	1–3 times daily	Similar kinetics to sermorelin but works through different receptor. Appetite stimulation limits use in some populations.

Sermorelin's position in this comparison highlights the trade-off between half-life and receptor dynamics. Longer half-life compounds reduce injection frequency but may compromise the pulsatile secretion pattern that defines healthy GH physiology. For researchers prioritizing circadian alignment and long-term receptor health, sermorelin's brief plasma presence is a feature, not a limitation.

What If: Sermorelin Dosing Scenarios

What If I Dose Sermorelin Multiple Times Per Day?

Administering sermorelin more than once daily provides no additional GH benefit and may reduce overall effectiveness. Each injection triggers a pituitary GH pulse that lasts 2–4 hours. Administering a second dose during that window hits a refractory period where the pituitary is already releasing stored GH. The second injection produces minimal incremental response. Worse, frequent dosing can desensitize GHRH receptors through tonic stimulation, blunting future pulses. If your goal is sustained GH elevation throughout the day, a single nightly sermorelin dose combined with daytime ipamorelin (a ghrelin receptor agonist with complementary kinetics) produces better synergy than multiple sermorelin injections.

What If I Miss My Bedtime Dose?

Missing a nightly sermorelin dose means you forfeit that evening's amplified GH pulse, but it doesn't disrupt the overall protocol. Do not double-dose the following night. This won't compensate for the missed pulse and may cause an exaggerated GH spike that triggers feedback inhibition. Resume your normal schedule the next evening. Sermorelin's short half-life means there's no cumulative plasma buildup, so skipping a dose doesn't create a deficit that compounds over time. Consistency matters more than perfection: five well-timed doses per week outperform erratic daily dosing.

What If I Inject Sermorelin in the Morning Instead of at Night?

Morning sermorelin administration works mechanistically but misses the largest natural GH pulse, which occurs 60–90 minutes after sleep onset. Injecting in the morning amplifies a smaller endogenous pulse, yielding lower peak GH levels than a bedtime dose would produce. Some protocols intentionally use morning dosing to support daytime anabolic processes (muscle protein synthesis, lipolysis) when combined with resistance training. If your primary goal is maximizing total GH output, bedtime dosing remains superior. If your goal is daytime metabolic support, morning administration paired with a second secretagogue (like ipamorelin) later in the day can create a staggered pulse pattern.

The Blunt Truth About Sermorelin Half-Life

Here's the honest answer: sermorelin's 10–20 minute half-life is irrelevant to its effectiveness, and anyone designing a dosing protocol based on plasma clearance time fundamentally misunderstands how GH secretagogues work. The peptide's job is to trigger a cascade. Once the pituitary pulse begins, sermorelin's continued presence contributes nothing. Extending half-life through chemical modification (as with CJC-1295 DAC) doesn't improve outcomes; it just shifts the mechanism from pulsatile to tonic, which degrades receptor sensitivity over time. The short half-life is part of the design. It mimics the brief GHRH bursts that occur naturally and preserves the body's regulatory feedback loops. Trying to "fix" sermorelin's brief circulation time is solving a problem that doesn't exist.

Sermorelin Storage and Reconstitution Impact

Sermorelin is supplied as lyophilized powder that must be reconstituted with bacteriostatic water before injection. Once reconstituted, the peptide remains stable at 2–8°C (refrigerated) for approximately 28 days. The rapid degradation that defines sermorelin's 10–20 minute plasma half-life also makes it vulnerable to temperature excursions during storage. A single exposure to temperatures above 25°C for more than 4 hours can trigger partial degradation. The resulting solution may look identical but deliver reduced GH response.

Our experience reviewing peptide handling protocols reveals that storage failures occur more often than injection errors. Sermorelin stored at room temperature or subjected to freeze-thaw cycles loses potency unpredictably. Unlike some peptides where degradation produces visible aggregation or cloudiness, sermorelin breakdown is not always apparent. The only reliable test is biological response. If expected GH pulses diminish despite consistent dosing, temperature compromise is a likely cause. Unreconstituted lyophilized sermorelin stored at −20°C remains stable for 12–24 months; once mixed, refrigeration is mandatory.

The interplay between chemical stability (storage half-life) and biological half-life (plasma clearance) defines peptide handling requirements. Sermorelin's brief circulation time doesn't make it fragile in vivo. Enzymatic degradation is a controlled biological process. Chemical degradation from heat or pH shifts, by contrast, is irreversible and eliminates therapeutic activity before the peptide reaches circulation.

When sourcing research-grade peptides, purity and handling matter as much as the compound itself. At Real Peptides, every batch undergoes third-party verification for exact amino-acid sequencing and is shipped with cold-chain integrity maintained throughout transit. If you're working with sermorelin in a research context, verifying that your supplier can document unbroken refrigeration from synthesis to delivery eliminates the single largest variable in peptide efficacy.

What's the half-life of sermorelin in practical terms? It's the 10–20 minutes the molecule spends in plasma before enzymatic cleavage. But the functional window extends hours beyond that through the GH pulse it initiates. Dosing protocols built around plasma half-life miss the mechanism entirely. The peptide's value lies in its ability to restore physiological pulsatility, not in maintaining steady-state plasma levels. If someone's trying to sell you a "longer-lasting sermorelin alternative" by extending circulation time, they're optimizing the wrong variable.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Sermorelin remains detectable in plasma for approximately 30–40 minutes after subcutaneous injection. The peptide reaches peak plasma concentration at 15–20 minutes and is then rapidly degraded by enzymes (DPP-IV and neprilysin), reducing levels by half every 10–20 minutes. While the peptide itself clears quickly, the growth hormone release it triggers peaks 30–60 minutes post-injection and can remain elevated for 2–4 hours.

Administering sermorelin twice daily does not meaningfully increase GH output and may reduce long-term effectiveness. Each dose triggers a 2–4 hour GH pulse; a second dose during that window encounters a refractory period where the pituitary is already releasing stored GH. Frequent dosing can also desensitize GHRH receptors through tonic stimulation, blunting future responses. For sustained GH elevation, combining sermorelin at night with a complementary secretagogue like ipamorelin during the day produces better synergy than multiple sermorelin injections.

Sermorelin’s plasma half-life (10–20 minutes) measures how quickly the peptide is cleared from circulation, while its duration of action (2–4 hours) measures how long GH levels remain elevated after the initial trigger. The peptide binds to GHRH receptors and initiates a cascade that continues long after sermorelin itself has degraded. This temporal disconnect is why dosing frequency is based on physiological GH pulse timing rather than plasma clearance — the mechanism operates through signal transduction, not sustained receptor occupancy.

Research-grade sermorelin typically costs 60–80% less than pharmaceutical recombinant human growth hormone (rhGH) for comparable therapeutic goals. A month’s supply of sermorelin at standard research doses ranges from $150–$300, while rhGH therapy often exceeds $1,000–$1,500 monthly. The cost difference reflects sermorelin’s mechanism — it stimulates endogenous GH production rather than replacing it — which requires lower per-dose expense but depends on intact pituitary function to work.

Reconstituted sermorelin exposed to room temperature (20–25°C) for 8–12 hours undergoes partial degradation that reduces biological activity, though the solution may appear visually unchanged. A single overnight excursion won’t render the peptide completely inactive, but potency loss is cumulative — repeated temperature violations compound degradation. If sermorelin was left unrefrigerated for less than 12 hours and has been stored correctly otherwise, it may still produce a measurable GH response, though likely attenuated. Temperatures above 30°C for more than 4 hours cause significant irreversible breakdown.

Sermorelin is dosed at bedtime to amplify the largest natural growth hormone pulse, which occurs 60–90 minutes after sleep onset. The peptide’s 10–20 minute plasma half-life is irrelevant to timing — what matters is triggering the pituitary release during the window when endogenous GHRH secretion peaks. Dosing at night aligns with circadian GH rhythm, producing higher peak GH levels than morning or midday administration. The rapid clearance prevents tonic receptor activation, preserving the pulsatile pattern that defines healthy GH physiology.

Sermorelin effectiveness depends directly on pituitary GH reserves and somatotroph receptor density — if those are depleted, sermorelin cannot create GH release from nothing. Age-related pituitary decline reduces response magnitude: a 25-year-old may see 300–500% GH increase post-injection, while a 65-year-old with diminished reserves might see only 50–100% elevation from the same dose. Sermorelin amplifies endogenous pulses; it does not replace absent GH production. Individuals with severe GH deficiency or pituitary damage require exogenous rhGH, not secretagogues.

CJC-1295 with DAC has a 6–8 day half-life through albumin binding, but this extended circulation produces continuous low-level GH elevation rather than physiological pulses. Chronic tonic stimulation can desensitize GHRH receptors over time, reducing responsiveness to subsequent doses. Sermorelin’s brief half-life preserves pulsatile secretion and receptor sensitivity, which is why protocols using sermorelin 5 days per week often maintain long-term efficacy better than daily CJC-1295 DAC. The longer half-life is not inherently superior — it represents a different mechanism with different trade-offs.

Daily sermorelin use over several months can lead to gradual receptor desensitization, particularly if dosed without rest days. GHRH receptors downregulate in response to continuous stimulation, blunting the GH pulse magnitude over time. Protocols incorporating 2 rest days per week (5-on-2-off schedule) allow receptor resensitization and often maintain stronger responses long-term compared to uninterrupted daily dosing. Some research suggests cycling sermorelin in 8–12 week blocks with 2–4 week breaks preserves receptor sensitivity and prevents tolerance buildup.

Mixing sermorelin with other peptides in the same syringe does not alter its plasma half-life — enzymatic degradation occurs post-injection based on the peptide’s amino acid structure, not on what else was co-administered. However, combining sermorelin with ghrelin receptor agonists (like ipamorelin or GHRP-2) can extend the functional GH elevation window through synergistic mechanisms: GHRH agonists trigger pituitary release while ghrelin agonists inhibit somatostatin, which would otherwise blunt the GH pulse. The half-life remains 10–20 minutes; the duration of elevated GH can extend to 4–6 hours with proper stacking.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA